BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$78.17−1.37 (-1.72%)
Close on Nov 12, 2026Market cap $15.23BP/E –Yield –
BridgeBio Pharma operating margin
Operating margin is operating income as a percentage of revenue.
BridgeBio Pharma's operating margin for the twelve months ending Sep 30, 2026 was -38.5%. For fiscal 2025 it was -104.2%, against -267.2% the year before. The highest annual figure on record is -104.2% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -104.2% | +163.0 |
| FY2024 | Dec 31, 2024 | -267.2% | +6261.5 |
| FY2023 | Dec 31, 2023 | -6528.8% | −5869.1 |
| FY2022 | Dec 31, 2022 | -659.6% | +167.5 |
| FY2021 | Dec 31, 2021 | -827.1% | +4924.9 |
| FY2020 | Dec 31, 2020 | -5752.0% | −5095.6 |
| FY2019 | Dec 31, 2019 | -656.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -3.3% | +117.0 |
| Q2 FY2026 | Jun 30, 2026 | -43.9% | +77.5 |
| Q1 FY2026 | Mar 31, 2026 | -54.5% | +35.0 |
| Q4 FY2025 | Dec 31, 2025 | -90.5% | +3752.2 |
| Q3 FY2025 | Sep 30, 2025 | -120.3% | +6898.4 |
| Q2 FY2025 | Jun 30, 2025 | -121.4% | +7975.4 |
| Q1 FY2025 | Mar 31, 2025 | -89.5% | −89.7 |
| Q4 FY2024 | Dec 31, 2024 | -3842.7% | +6324.4 |
| Q3 FY2024 | Sep 30, 2024 | -7018.7% | −3164.1 |
| Q2 FY2024 | Jun 30, 2024 | -8096.8% | +806.2 |
| Q1 FY2024 | Mar 31, 2024 | 0.2% | +6909.4 |
| Q4 FY2023 | Dec 31, 2023 | -10167.1% | −3256.3 |
| Q3 FY2023 | Sep 30, 2023 | -3854.6% | +34345.4 |
| Q2 FY2023 | Jun 30, 2023 | -8903.0% | −8794.3 |
| Q1 FY2023 | Mar 31, 2023 | -6909.3% | +3343.3 |
| Q4 FY2022 | Dec 31, 2022 | -6910.8% | −5625.6 |
| Q3 FY2022 | Sep 30, 2022 | -38200.0% | −31822.1 |
| Q2 FY2022 | Jun 30, 2022 | -108.7% | +65.3 |
| Q1 FY2022 | Mar 31, 2022 | -10252.5% | +26003.7 |
| Q4 FY2021 | Dec 31, 2021 | -1285.2% | +103214.0 |
| Q3 FY2021 | Sep 30, 2021 | -6377.9% | −4902.1 |
| Q2 FY2021 | Jun 30, 2021 | -174.0% | +395.0 |
| Q1 FY2021 | Mar 31, 2021 | -36256.3% | −36052.4 |
| Q4 FY2020 | Dec 31, 2020 | -104499.2% | – |
| Q3 FY2020 | Sep 30, 2020 | -1475.8% | – |
| Q4 FY2019 | Dec 31, 2019 | -569.1% | – |
| Q3 FY2019 | Sep 30, 2019 | -203.9% | – |
See a number that looks wrong?